Central Nervous System Response to Selpercartinib in Patient With RET-rearranged Non-small Cell Lung Cancer After Developing Leptomeningeal Disease on Pralsetinib

Clin Lung Cancer. 2022 Jan;23(1):e5-e8. doi: 10.1016/j.cllc.2021.06.005. Epub 2021 Jun 12.

Authors

David Chun Cheong Tsui¹, Brian D Kavanagh², Justin M Honce³, Candice Rossi¹, Tejas Patil¹, D Ross Camidge⁴

Affiliations

¹ Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO.
² Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, CO.
³ Department of Radiology, University of Colorado Anschutz Medical, Aurora, CO.
⁴ Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO. Electronic address: ross.camidge@cuanschutz.edu.

PMID: 34246540
DOI: 10.1016/j.cllc.2021.06.005

No abstract available

Keywords: NSCLC; RET; leptomeningeal; pralsetinib; selpercatinib.

Publication types

Case Reports

MeSH terms

Antineoplastic Agents / pharmacology*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Central Nervous System / drug effects*
Central Nervous System / physiopathology*
Female
Humans
Lung Neoplasms / drug therapy*
Meningeal Neoplasms
Middle Aged
Proto-Oncogene Proteins c-ret*
Pyrazoles / pharmacology*
Pyrazoles / therapeutic use*
Pyridines / pharmacology*
Pyridines / therapeutic use*
Pyrimidines / pharmacology*
Pyrimidines / therapeutic use*

Substances

Antineoplastic Agents
Pyrazoles
Pyridines
Pyrimidines
pralsetinib
selpercatinib
Proto-Oncogene Proteins c-ret
RET protein, human